I'm not doubting every step they are taking. I'm trying to believe the company when they tell me that Plexus is responsible for deal origination for the rest of the world outside of China.
So what you are saying is this is incorrect and deal interest originated to date in South America and MENA has somehow been originated by PAR itself? Because Plexus has no interest dealing in these markets.
Now we have Scott Williams with ZERO experience in biotech deal negotiations bringing our regional deals home. Great, thanks for clarifying.
Ann: PAR Appoints Business Development Consultant, page-127
-
- There are more pages in this discussion • 201 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |